ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML
Abstract
Acute myeloid leukemia (AML) treatments often cause profound immunosuppression, limiting immune-mediated control of residual disease. DIMATE, an ALDH1 inhibitor under clinical evaluation, induces aldehyde and redox stress in leukemic cells, but its impact on immune effector functions and tumor immunogenicity remains insufficiently defined. Here, we assessed the effects of DIMATE on human immune cells and AML models, including peripheral blood mononuclear cells, AML cell lines, and primary AML samples. DIMATE largely preserved selected immune effector functions at pharmacologically relevant concentrations, including T-cell activation, natural killer cell cytotoxicity, and phagocyte oxidative burst. In parallel, DIMATE induced pro-inflammatory and endoplasmic reticulum stress pathways in AML cells, upregulated co-stimulatory molecules, and promoted ICD-compatible features, including ecto-calreticulin exposure. These findings suggest that DIMATE may couple immune preservation with enhanced leukemic immunogenicity, supporting its potential for combination with immune-engaging therapies and strategies targeting measurable residual disease in AML, but also as a single agent capable of fostering a more immunostimulatory anti-leukemic context.
Related
- STAT3 inhibition for the induction of immunogenic cell death in multiple myeloma
- TMEM55B Maintains Lysosomal Homeostasis and Promotes ER–Lysosome Calcium Signaling
- Ultrasound-induced immunogenic cell death in cancer: mechanisms, immune remodeling, and therapeutic opportunities
- Oral artificial microbio-vaccine triggers synergistic immunogenic cell death induction and tumor microenvironment remodeling for liver cancer therapy.
- Surface curvature promotes coordinated extracellular matrix remodeling and mechanotransductive signaling during osteoblast adaptation
BibTeX
@article{baier2026aldh1,
title = {{ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML}},
author = {Céline Baier and Julien Colle and Yasmine Labiad and Pascal Rihet and Mileidys Pérez-Alea and Béatrice Loriod and Ismail Ceylan and Geoffroy Venton and Guillaume Martin and Régis Costello},
journal = {Frontiers in Immunology},
year = {2026},
month = aug,
doi = {10.3389/fimmu.2026.1876637},
url = {https://amu.hal.science/hal-05835058v1},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML
AU - Céline Baier
AU - Julien Colle
AU - Yasmine Labiad
AU - Pascal Rihet
AU - Mileidys Pérez-Alea
AU - Béatrice Loriod
AU - Ismail Ceylan
AU - Geoffroy Venton
AU - Guillaume Martin
AU - Régis Costello
PY - 2026
DA - 2026/08/12
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1876637
UR - https://amu.hal.science/hal-05835058v1
AB - Acute myeloid leukemia (AML) treatments often cause profound immunosuppression, limiting immune-mediated control of residual disease. DIMATE, an ALDH1 inhibitor under clinical evaluation, induces aldehyde and redox stress in leukemic cells, but its impact on immune effector functions and tumor immunogenicity remains insufficiently defined. Here, we assessed the effects of DIMATE on human immune cells and AML models, including peripheral blood mononuclear cells, AML cell lines, and primary AML samples. DIMATE largely preserved selected immune effector functions at pharmacologically relevant concentrations, including T-cell activation, natural killer cell cytotoxicity, and phagocyte oxidative burst. In parallel, DIMATE induced pro-inflammatory and endoplasmic reticulum stress pathways in AML cells, upregulated co-stimulatory molecules, and promoted ICD-compatible features, including ecto-calreticulin exposure. These findings suggest that DIMATE may couple immune preservation with enhanced leukemic immunogenicity, supporting its potential for combination with immune-engaging therapies and strategies targeting measurable residual disease in AML, but also as a single agent capable of fostering a more immunostimulatory anti-leukemic context.
SN - 1664-3224
SN - 1664-3224
ER -